4D Molecular Therapeutics Inc
NASDAQ:FDMT
Intrinsic Value
4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. [ Read More ]
The intrinsic value of one
FDMT
stock under the Base Case scenario is
0.33
USD.
Compared to the current market price of 25.25 USD,
4D Molecular Therapeutics Inc
is
Overvalued by 99%.
FDMT's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
FDMT or that its price is influenced by factors unrelated to fundamentals.
4D Molecular Therapeutics Inc's market capitalization is 1.3B USD.
FDMT stock price is 25.25 USD.
FDMT stock (0.33 USD) is 99% less than its price (25.25 USD).
FDMT. Open DCF Valuation
FDMT stock (0.33 USD) is 99% less than its price (25.25 USD). Open Relative Valuation
FDMT has upside potential of 111% compared to the average analyst price target.
Open Wall St Estimates
FDMT's ROE (Return on Equity) has significantly decreased in the last 3 years from -27% to -37%, and is approaching profitability.
FDMT's Revenue has grown by an exceptional 562% over the past 12 months.
FDMT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -468% to -243%, and is approaching profitability.
FDMT has negative Operating Income for the last twelve months.
FDMT has negative Net Income for the last twelve months.
FDMT's ROE (Return on Equity) for the past 12 months is negative and is equal to -37%.
FDMT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -243%.
FDMT's Revenue is forecast to fall at a rate of 54% per year over the next 3 years.
FDMT has negative Free Cash Flow for the last twelve months.
FDMT has negative three-year average ROE (Return on Equity): -36%. The company is not efficient at transforming stockholders' equity into net income.
FDMT has negative three-year average ROIC (Return on Invested Capital): -250%. The company is not efficient at using invested capital to generate operating income.
FDMT's short-term assets (297m USD) exceed its short-term liabilties (19m USD).
FDMT's long-term assets (340m USD) exceed its long-term liabilties (32m USD).
FDMT's D/E (Debt to Equity) is very low and is equal to 0.
FDMT's Altman Z-Score is very high and is equal to 16.09.
Valuation Backtest
4D Molecular Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
FDMT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
4D Molecular Therapeutics Inc
Balance Sheet Decomposition
4D Molecular Therapeutics Inc
| Current Assets | 296.6m |
| Cash & Short-Term Investments | 288.2m |
| Other Current Assets | 8.4m |
| Non-Current Assets | 43.3m |
| Long-Term Investments | 11m |
| PP&E | 31.7m |
| Other Non-Current Assets | 684k |
| Current Liabilities | 19m |
| Accounts Payable | 3.5m |
| Accrued Liabilities | 13.6m |
| Other Current Liabilities | 1.9m |
| Non-Current Liabilities | 13.1m |
| Other Non-Current Liabilities | 13.1m |
Earnings Waterfall
4D Molecular Therapeutics Inc
|
Revenue
|
20.7m
USD
|
|
Operating Expenses
|
-133.6m
USD
|
|
Operating Income
|
-112.9m
USD
|
|
Other Expenses
|
12m
USD
|
|
Net Income
|
-100.8m
USD
|
Free Cash Flow Analysis
4D Molecular Therapeutics Inc
What is Free Cash Flow?
FDMT Profitability Score
Profitability Due Diligence
4D Molecular Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
4D Molecular Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
FDMT Solvency Score
Solvency Due Diligence
4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
4D Molecular Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FDMT Price Targets Summary
4D Molecular Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
FDMT
is 53.24 USD
with a low forecast of 34.34 USD and a high forecast of 86.1 USD.
Ownership
FDMT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FDMT Price
4D Molecular Therapeutics Inc
| Average Annual Return | 5.04% |
| Standard Deviation of Annual Returns | 53.27% |
| Max Drawdown | -89% |
| Market Capitalization | 1.3B USD |
| Shares Outstanding | 49 780 000 |
| Percentage of Shares Shorted | 23.4% |
Company Profile
4D Molecular Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
4D Molecular Therapeutics, Inc. engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 124 full-time employees. The company went IPO on 2020-12-11. The firm is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The firm's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The firm is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).
Contact
IPO
Employees
Officers
The intrinsic value of one
FDMT
stock under the Base Case scenario is
0.33
USD.
Compared to the current market price of 25.25 USD,
4D Molecular Therapeutics Inc
is
Overvalued by 99%.
You don't have any saved screeners yet
